Highlights bluebird bio, Inc.

Equities

BLUE

US09609G1004

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
0.9746 ^USD	-3.50%		+7.18%	-29.38%

05-06	Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy	CI
04-26	Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy	05-06	CI
Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report	04-26	MT
Bluebird bio to Restate Financial Statements; Shares Fall	03-26	MT
Gene therapy maker bluebird to restate 2022 financials after accounting error	03-26	RE
Bluebird bio Signs Medicaid Agreement for Sickle Cell Disease Therapy with Michigan State	03-11	MT
Bluebird bio, Inc. Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy	03-11	CI
Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels	12-11	CI
Bluebird bio, Inc. Announces Long-term Follow-up Data From It's Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events	12-09	CI
Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events	12-08	CI
Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA?? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events	12-08	CI
US approves two gene therapies for sickle cell disease	12-08	RE
Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M	11-07	MT
Bluebird bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition	11-02	CI
Bluebird bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (BLUE) BLUEBIRD BIO Reports Q2 Revenue $6.9M	23-08-08	MT
Bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease 12 Years and Older with a History of Vaso-Occlusive Events	23-06-21	CI
Earnings Flash (BLUE) BLUEBIRD BIO Reports Q1 Revenue $2.4M, vs. Street Est of $27M	23-05-09	MT
Bluebird bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Bluebird bio submits US marketing application for blood disorder gene therapy	23-04-24	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights bluebird bio, Inc.

Equities

BLUE

US09609G1004

Highlights

Filters